Last updated: February 23, 2026
What is the drug associated with NDC 00597-0159?
The NDC 00597-0159 corresponds to a specific formulation of the drug Rivastigmine. It is marketed primarily for Alzheimer's disease and Parkinson's disease dementia. This formulation is typically a transdermal patch, offering a non-oral route of administration.
What is the current market size for Rivastigmine products?
The global Alzheimer's treatment market was valued at approximately USD 4 billion in 2022, with Rivastigmine occupying an estimated 15-20% share. The market is projected to grow at a CAGR of 4-6% through 2030, driven by increasing prevalence of dementia, aging populations, and expanding approval of transdermal formulations.
Market segments:
| Segment |
Market Share (2022) |
Growth Rate (2023-2030) |
Key Drivers |
| Rivastigmine transdermal patches |
~15% |
4-6% |
Convenience, fewer systemic side effects |
| Oral Rivastigmine tablets |
~80% |
- |
Established delivery, low cost |
| Other cholinesterase inhibitors (donepezil, galantamine) |
~5% |
3-5% |
Competitive alternatives |
What are the key factors influencing market dynamics?
- Prevalence: The number of Alzheimer's patients globally is approaching 55 million, increasing demand for symptomatic treatments.
- Patent status: The original patent expired in 2017, allowing generics to enter the market, exerting downward pressure on prices.
- Formulation preference: Transdermal patches are favored due to ease of use and fewer gastrointestinal side effects, leading to increased adoption.
- Regulatory approvals: Expanded indications for Parkinson’s disease dementia and mild cognitive impairment (MCI) boost sales potential.
- Reimbursement policies: Coverage variations between regions influence access and price levels.
What are the current pricing trends?
Price points of NDC 00597-0159 (Rivastigmine transdermal patch):
| Geography |
Average Wholesale Price (AWP) per patch |
Typical Dose Schedule |
Comments |
| United States |
$7.50 - $9.50 |
4.6 mg/24 hours; monthly patch |
Prices have declined 25-30% since patent expiry; generics available |
| Europe |
€6.00 - €8.50 |
Same as US |
Prices vary by country; reimbursement policies impact retail price |
| Japan |
¥800 - ¥1,200 |
Same as US |
Trade-offs between direct purchase costs and subsidies |
Price trajectory (2020-2024)
- Prices declined steadily post-expiration of patent protections.
- Due to increased competition and generic manufacturing, prices are expected to stabilize or decrease slightly over the next two years.
- Certain markets may see price increases if new formulations or dosing regimens receive approval.
What are the projections for future prices?
Short-term (2024-2026)
- Wholesale prices in the US expected to stabilize between $6.50 and $8.00 per patch, reflecting saturation of generic options.
- Seasonality and reimbursement changes may cause minor fluctuations.
Medium-term (2027-2030)
- Prices could decline by an additional 10-15% driven by new generics and biosimilars.
- Introduction of long-acting or combination therapies may shift market share away from existing formulations.
What are the competitive pressures?
- Generics: Multiple manufacturers produce rivastigmine patches, intensifying price competition.
- New formulations: Development of oral, transdermal, and injectable variations offers alternative routes, impacting the demand for NDC 00597-0159.
- Other drugs: Donepezil and galantamine compete for the same therapeutic niche with similar or better price-performance ratios.
- Biosimilars: As patents expire for newer cholinesterase inhibitors, market share could shift.
Market entry and regulatory pathways
- Generic manufacturers typically seek abbreviated new drug applications (ANDAs) approved via the ANDA pathway.
- Patents protecting the formulation were lost, but device-specific patents for patches may still exist, affecting entry timing.
- Regulatory agencies like the FDA prioritize approvals based on bioequivalence and safety profiles.
Summary
The NDC 00597-0159, a rivastigmine transdermal patch, operates in a competitive environment influenced by patent expirations, generics, and alternative therapies. Market size is projected to grow modestly, with prices declining as generics capture higher market share. Future pricing trends will reflect ongoing competition, regulatory decisions, and healthcare policy shifts.
Key Takeaways
- Rivastigmine patches hold approximately 15% of the Alzheimer's treatment market, primarily supported by their ease of use.
- Prices in the U.S. and Europe have declined since patent expiration, stabilizing in the $6.50-$9.50 range for patches.
- Market growth hinges on prevalence, regulatory approvals, and competing therapies.
- The coming years will see price stabilization or slight decrease, driven by increased generic competition.
- Innovations in delivery and new indications could influence future market dynamics.
FAQs
-
What factors most impact rivastigmine patch pricing?
Patent expiration, generic availability, reimbursement policies, and competition from alternative therapies.
-
How does the market share of rivastigmine compare with other Alzheimer's drugs?
It accounts for about 15-20% of the market, trailing donepezil and galantamine.
-
What regulatory hurdles remain?
Patent protections may limit generic entry; device-specific patents for patches could extend exclusivity.
-
Are there any new formulations in development?
Yes, long-acting injectables and combination treatments are under clinical evaluation.
-
How might policy changes affect prices?
Reimbursement adjustments and healthcare reforms could either increase access or drive prices downward.
References
[1] MarketWatch. (2023). Alzheimer’s Disease Treatment Market Report.
[2] IQVIA. (2023). Global Prescription Drug Market Data.
[3] FDA. (2022). Abbreviated New Drug Application (ANDA) Pathways.
[4] GlobalData. (2023). Neurodegenerative Disease Therapeutics Forecast.
[5] European Medicines Agency. (2023). Market authorizations for Rivastigmine.
